Education
About Us
Working with TipRanks
Follow Us
COSMO Pharmaceuticals N.V. (GB:0RGI)
LSE:0RGI
0RGI Stock Chart & Stats
CHF75.80
CHF1.30(2.05%)
At close: 4:00 PM EST
CHF75.80
CHF1.30(2.05%)
Day’s Range― - ―
52-Week RangeCHF41.65 - CHF129.60
Previous CloseN/A
Volume9.00
Average Volume (3M)2.64K
Market Cap
CHF1.28B
Enterprise ValueCHF1.29B
Total Cash (Recent Filing)CHF122.66M
Total Debt (Recent Filing)CHF4.26M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Jul 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.8%
Share Statistics
EPS (TTM)-0.02
Shares Outstanding17,543,522
10 Day Avg. Volume3,564
30 Day Avg. Volume2,637
Financial Highlights & Ratios
PEG Ratio4.83
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF140.00Price Target Upside84.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.91
Revenue Forecast (FY)CHF127.47M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetMinimal leverage and substantial equity give the company enduring financial flexibility. A conservative balance sheet reduces refinancing and liquidity risk, supports continued R&D or licensing investments, and provides runway to manage operational volatility over the next several months without forcing distressed asset sales.
Focused Gastroenterology FranchiseA clear specialty focus on gastroenterology builds durable clinical relationships and repeatable demand from endoscopy centers. The mix of direct commercialization and licensing creates diversified revenue channels and optionality: upfront, milestone and royalty economics can materially de-risk reliance on a single sales model over the medium term.
Demonstrated High-margin Cash GenerationThe company proved it can deliver very high margins and strong free cash flow in favorable years, showing its products/partnerships can scale profitably. This track record indicates structural upside potential when commercial execution aligns, and supports the case that earnings can rebound to self-funding levels if demand stabilizes.
Bears Say
Sharp Recent Revenue And Profit DeclineA large, abrupt drop in revenue and transition to negative margins materially reduces near-term visibility. Such a decline suggests product/market concentration or lost sales momentum, raising the risk that revenue weakness persists and limits the company's ability to fund operations or reinvest in growth without using balance sheet reserves or external partners.
Negative Operating And Free Cash FlowA swing to cash burn removes the company's self-funding cushion and increases dependence on balance sheet resources or external financing. Over a multi-month horizon, negative cash flow constrains R&D, commercialization investments and flexibility in licensing negotiations, raising execution and funding risk during recovery efforts.
High Earnings VolatilityInconsistent profitability across years undermines forecasting and partner confidence. Persistent earnings volatility complicates long-term planning for commercialization and pricing, increases perceived execution risk among counterparties, and makes sustainable margin improvement and predictable cash generation harder to achieve over the coming months.
COSMO Pharmaceuticals N.V. News
0RGI FAQ
What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?
COSMO Pharmaceuticals N.V. lowest share price was CHF41.65 and its highest was CHF129.60 in the past 12 months.
What is COSMO Pharmaceuticals N.V.’s market cap?
COSMO Pharmaceuticals N.V.’s market cap is CHF1.28B.
When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?
COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Jul 29, 2026 which is in 128 days.
How were COSMO Pharmaceuticals N.V.’s earnings last quarter?
COSMO Pharmaceuticals N.V. released its earnings results on Mar 09, 2026. The company reported -CHF0.018 earnings per share for the quarter, missing the consensus estimate of CHF0.182 by -CHF0.2.
Is COSMO Pharmaceuticals N.V. overvalued?
According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued.
Does COSMO Pharmaceuticals N.V. pay dividends?
COSMO Pharmaceuticals N.V. pays a Annually dividend of CHF1.788 which represents an annual dividend yield of 1.8%. See more information on COSMO Pharmaceuticals N.V. dividends here
What is COSMO Pharmaceuticals N.V.’s EPS estimate?
COSMO Pharmaceuticals N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSMO Pharmaceuticals N.V. have?
COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.
What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?
COSMO Pharmaceuticals N.V. reported an EPS of -CHF0.018 in its last earnings report, missing expectations of CHF0.182. Following the earnings report the stock price went down -7.972%.
Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?
Currently, no hedge funds are holding shares in GB:0RGI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
0RGI Stock 12 Month Forecast
Average Price Target
CHF140.00
▲(84.70% Upside)
Technical Analysis
Roche Holding AG
―
Basilea Pharmaceutica
―
Kuros Biosciences
―
medmix AG
―
Medartis Holding AG
―
Options Prices
Currently, No data available
---